Glucosylceramide synthase inhibitors

US12060349B2 · kind B2 · utility

Assignee

• Genzyme Corporation · US

Inventors

• Elyse Bourque · Langley, CA
• Mario CABRERA-SALAZAR · Watertown, US
• Cassandra Celatka · Hull, US
• Seng H. Cheng · Wellesley, US
• Bradford H. Hirth · Framingham, US
• Andrew C. Good · Wallingford, US
• Katherine JANCSICS · Wilmington, US
• John Marshall · Milford, US
• Markus Metz · Bellevue, US
• Ronald K. Scheule · Hopkinton, US
• Renato Skerlj · Vancouver, CA
• Yibin Xiang · Dracut, US
• Zhong Zhao · Munich, DE
• John Leonard · Manchester, US
• Thomas A. Natoli · Revere, US
• Elina Makino · Winchester, US
• Herve Husson · Boston, US
• Oxana Beskrovnaya · Southborough, US

Key dates

• Filing date: Apr 14, 2021
• Grant date: Aug 13, 2024
• Expiry date: May 20, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to inhibitors of glucosylceramide synthase (GCS) of the Formula I: represented by the following structural formula or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.